Registration Header

Jounce R&D Day

Start Date:6/23/2021

Start Time:10:00 AM EDT

Duration:120 minutes

Agenda for today.

- CEO Welcome
- KOL Presentation 
- R&D Presentation: Sustainable Drug Development at Jounce 
        -Translational Science Platform – Interrogating the Tumor
                   - JTX-8064 Case Study: 
                           - Discovery and Preclinical Development
                           - Translational: Biomarkers and Indication Selection
                           - Clinical Strategy 
- Q&A

If you're already registered for the Jounce R&D Day webcast, click below:



Robert Schreiber, PhD

The Washington University School of Medicine

Andrew M. Bursky and Jane M. Bursky Distinguished Professor of Pathology and Immunology, Professor of Molecular Microbiology, co-leader of the tumor immunology program at the Siteman Comprehensive Cancer Center and founding Director of the Center for Human Immunology and Immunotherapy Programs at The Washington University School of Medicine in St. Louis, Missouri A leader in the study of tumor immunology, Bob Schreiber is a senior scientific adviser to Jounce Therapeutics and currently serves as the alumni endowed professor of pathology and immunology, professor of molecular microbiology, co-leader of the tumor immunology program for the Siteman Comprehensive Cancer Center, and director of the Center for Human Immunology and Immunotherapy Programs (CHiiPs) at Washington University School of Medicine in St. Louis. He is an associate director of the Cancer Research Institute, a member of the US National Academy of Sciences and the American Academy of Arts and Sciences, a fellow of the American Association of Science, a past member of the board of scientific advisers for the National Cancer Institute, and a past president of the Society for Leukocyte Biology. Dr. Schreiber has led a major revision in our understanding of how the immune system interacts with cancer. His work formed the basis for the concept of cancer immunoediting that helped reveal that the immune system is not only capable of destroying cancers, but can sometimes also either hold cancers in a dormant state or sculpt their immunogenicity thereby enhancing their malignancy. His lab is highly regarded for its research on the molecular cell biology and immunology of interferon-gamma and its receptor, as well as its strong expertise in mAb discovery. Dr. Schreiber’s group unequivocally demonstrated that the immune system provides an extrinsic tumor suppressor function (cancer immunosurveillance) capable of eliminating spontaneous- and carcinogen-induced primary tumors. He has authored more than 300 peer reviewed and invited publications and has received several honors, including the Milstein Award for Outstanding Achievements in Research on Interferon and Cytokines from the International Society of Interferon and Cytokine Research, the Bonazinga Award for Excellence in Leukocyte Biology Research from the Society for Leukocyte Biology, the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology from the Cancer Research Institute, the Charles Rodolphe Brupbacher Award for Cancer Research from the Brupbacher Cancer Foundation in Switzerland and the AACR-CRI Lloyd J. Old Award in Cancer Immunology awarded jointly by the American Association for Cancer Research and Cancer Research Institute.

Richard Murray, Ph.D.

Chief Executive Officer and President

Jounce Therapeutics

Richard Murray has served as Chief Executive Officer and President of Jounce Therapeutics, along with sitting on the Board of Directors, since July, 2014. He brings to Jounce more than two decades of biologics R&D leadership and experience moving product candidates through development to commercialization for both startup biotechnology and large pharmaceutical companies. Dr. Murray joined Jounce from Merck, where he most recently served as senior vice president, biologics & vaccines research. There, he was responsible for the advancement of protein therapeutics and vaccines across a breadth of therapeutic areas, from discovery through development and manufacturing, including Merck’s immunotherapy programs. Prior to joining Merck, Dr. Murray provided strategic and operational guidance to protein therapeutic biotech companies and served as an advisor to venture capital and life science investors. He was the executive vice president and chief scientific officer at PDL BioPharma, and previously, he was co-founder and vice president of research at EOS Biotechnology, which was acquired in 2003 by Protein Design Labs. Prior to these executive level roles, he spent more than 10 years on the staff at DNAX Research Institute, which later became Schering Plough Biopharma, and now Merck’s Biologics. Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst.

Dmitri Wiederschain Ph.D.

Chief Scientific Officer

Jounce Therapeutics

Dmitri Wiederschain, Ph.D., brings to Jounce more than 15 years of pharmaceutical industry experience as a scientific leader and drug developer. Dr. Wiederschain joins Jounce from Sanofi, where he held roles of increasing responsibility over the course of 11 years and helped build a pipeline encompassing a diverse array of immuno-oncology approaches. Most recently, he was vice president and global head of immuno-oncology research where he oversaw projects from conception to IND stage, built productive partnerships and research collaborations and advanced 10 development candidates into the clinic while leading a large international team of scientists in both the U.S. and France. Prior to joining Sanofi, Dr. Wiederschain was an investigator and laboratory head of discovery biology, and prior to that a presidential post-doctoral fellow in oncology at Novartis Institutes for Biomedical Research. He has co-authored 45 publications in peer-reviewed journals to date. Dr. Wiederschain holds a Ph.D. in Biological Sciences and an A.L.B. in Natural Sciences from Harvard University.

Yasmin Hashambhoy-Ramsay Ph.D.

Senior Principal Scientist, Translational Genomics

Jounce Therapeutics

Yasmin Hashambhoy-Ramsay, Ph.D., joined Jounce in April 2017 and leads the Translational Genomics team. She has made instrumental contributions to the JTX-8064 program and plays a key scientific role in the INNATE trial. Prior to joining Jounce, Dr. Hashambhoy-Ramsay spent 5 years as a computational biologist at Merrimack Pharmaceuticals, developing signaling and pharmacokinetics models to understand drug mechanism of action. Dr. Hashambhoy-Ramsay received her Ph.D. in biomedical engineering from Johns Hopkins University and a B.Sc. in Mathematics and Engineering from Queen’s University.

Haley Laken, Ph.D.

Senior Vice President, Program and Portfolio Strategy

Jounce Therapeutics

Haley Laken, Ph.D. joined Jounce in March 2018 and brings more than 20 years of experience in biotech and pharmaceutical large molecule drug development strategy and execution. Prior to joining Jounce, Dr. Laken established the immunotherapy pipeline at TESARO, advancing three new antibody candidates into the clinic in 18 months. She was also instrumental in the development of the program leadership and management function during a period of rapid growth and transition to a commercial stage company. Dr. Laken has held positions of increasing strategic drug development leadership at Rhythm Pharmaceuticals, Pfizer, and Wyeth. Dr. Laken received her Ph.D. in human genetics and molecular biology from Johns Hopkins University and a B.A. in biology from DePauw University.

Elizabeth Trehu, M.D.

Chief Medical Officer

Jounce Therapeutics

Elizabeth (Beth) Trehu, M.D., FACP, brings to Jounce more than 30 years of clinical experience, including 20 years in the biotech industry leading translational and integrated hematology and oncology drug development. Dr. Trehu designed and ran her first immunotherapy cancer trials in the early 90’s as a fellow and assistant professor of medicine at Tufts University School of Medicine, where she conducted preclinical and clinical research in immunotherapy with the NCI Cytokine Working Group. Dr. Trehu joined Jounce from Promedior, Inc., where she served as the chief medical officer. In this role, she led the creation and implementation of clinical development plans for Promedior’s lead macrophage product candidate, PRM-151, which led to the acquisition of Promedior by Roche in 2020. Prior to Promedior, Dr. Trehu served as vice president, oncology product development and medical affairs for Infinity Pharmaceuticals, and earlier, held various leadership positions at Genzyme Corporation, including vice president and general manager of hematology for Genzyme’s transplant oncology group, where she had global responsibility for Clolar®, Campath®, and Fludara®. Earlier in her career, Dr. Trehu held roles of increasing responsibility at Millennium Pharmaceuticals, including vice president, oncology global medical affairs, and was integral in the development and commercialization of VELCADE®. She was an internal medicine resident and chief resident at Georgetown University School of Medicine, where she also ran the transitional residency program. Dr. Trehu received her A.B. cum laude in English Literature from Princeton University and her M.D. from New York University School of Medicine. Dr. Trehu has served on the Board of Directors of Constellation Pharma, Inc. since 2018, where she is a member of the Research and Development Committee and Compensation Committee.

Kim Drapkin, CPA

Chief Financial Officer

Jounce Therapeutics

Kim Drapkin brings to Jounce more than 20 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. Ms. Kim Drapkin brings to Jounce more than 20 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. Ms. Drapkin has worked with Jounce since its inception, playing a key role in building Jounce’s financial infrastructure, and comes into this role with an already deep understanding of Jounce’s strategy and culture. Prior to joining Jounce, Ms. Drapkin owned a financial consulting firm where she served as the interim chief financial officer for numerous early-stage biotechnology companies, including Jounce, Eleven Biotherapeutics, Inc., NinePoint Medical, Inc., Blueprint Medicines Corporation, Warp Drive Bio LLC, Edimer Pharmaceuticals and Voyager Therapeutics, Inc. Previously, Ms. Drapkin was chief financial officer at EPIX Pharmaceuticals. Prior to EPIX, Ms. Drapkin spent ten years in roles of increasing responsibility within the finance organization at Millennium Pharmaceuticals. Ms. Drapkin began her career in the technology and life sciences practice at PriceWaterhouseCoopers LLP. Ms. Drapkin received her B.S. in accounting from Babson College.
First Name
Last Name
Email Address